Leslie’s, Inc. (NASDAQ:LESL – Get Free Report)’s stock price gapped down prior to trading on Tuesday after Robert W. Baird lowered their price target on the stock from $4.00 to $3.50. The stock had previously closed at $3.51, but opened at $2.78. Robert W. Baird currently has a neutral rating on the stock. Leslie’s shares last traded at $2.80, with a volume of 812,857 shares traded.
A number of other equities research analysts also recently weighed in on LESL. Mizuho cut their target price on Leslie’s from $6.00 to $4.00 and set a “neutral” rating for the company in a research report on Tuesday, August 6th. Telsey Advisory Group cut their price objective on Leslie’s from $4.00 to $3.75 and set a “market perform” rating for the company in a report on Tuesday. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat, Leslie’s presently has a consensus rating of “Hold” and a consensus price target of $3.89.
Check Out Our Latest Research Report on LESL
Institutional Inflows and Outflows
Leslie’s Stock Up 1.2 %
The firm has a market capitalization of $458.58 million, a PE ratio of -20.92, a price-to-earnings-growth ratio of 2.37 and a beta of 1.19. The business’s 50-day moving average price is $2.85 and its 200-day moving average price is $3.48.
Leslie’s Company Profile
Leslie’s, Inc operates as a direct-to-consumer pool and spa care brand in the United States. The company markets and sells pool and spa supplies and related products and services. It also offers various pool and spa maintenance items, such as chemicals, equipment and parts, cleaning and maintenance equipment, safety, recreational, and fitness related products.
Featured Stories
- Five stocks we like better than Leslie’s
- Most active stocks: Dollar volume vs share volume
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How to Invest in Blue Chip Stocks
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Upcoming IPO Stock Lockup Period, Explained
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Leslie's Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leslie's and related companies with MarketBeat.com's FREE daily email newsletter.